Live Chat ×
Skip to main content

Redefining Pre-Clinical Testing in Oncology: Why We Need to Go 3D- Recording

In the last ten years, there has been a dramatic surge in the number of publications where single or groups of cells are grown in substrata that have elements of basement membrane leading to the formation of tissue-like structures referred to as organoids. Moreover, evidence is accumulating that the development of organoid platforms represents a unique opportunity to redefine the traditional way of carrying out pre-clinical testing of new therapeutic strategies for cancer. This is critical given the low percentage of drugs that entering phase 1 actually make it to the clinic (5% in oncology). We will cover a historical perspective of the development of 3D-culture systems and show clear examples of how these new platforms represent a unique opportunity to improve the efficacy of the drug-development process.

Trying to Access Videos? Click PURCHASE below. You will see the Member/Non-Member rate once you sign in.

for SLAS Members
$20 for Non-Members